Maximilian Heinz Beck

2026

Additional file 1 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048940.v1

Supplementary Material 1.

2026

Additional file 1 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048940

Supplementary Material 1.

2026

Additional file 2 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048943

Supplementary Material 2.

2026

Additional file 2 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048943.v1

Supplementary Material 2.

2026

Additional file 3 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048946.v1

Supplementary Material 3.

2026

Additional file 3 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048946

Supplementary Material 3.

2026

Additional file 4 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048949.v1

Supplementary Material 4.

2026

Additional file 4 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.32048949

Supplementary Material 4.

2026

Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors

·doi:10.1016/j.ijgc.2025.103753

observational 2026

Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.c.8428212.v1

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

observational 2026

Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

·doi:10.6084/m9.figshare.c.8428212

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

observational 2026

Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence

BMC cancer ·doi:10.1186/s12885-026-15980-w

BACKGROUND: Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis independently …

2026

Multimodal analysis reveals asynchronous aging dynamics between endometriosis-associated ovarian cancer and endometriosis patients

·doi:10.1186/s12916-026-05101-6

Abstract Background The malignant transformation of endometriosis into endometriosis-associated ovarian cancer (EAOC) is still of great interest among researchers. Despite the shared inflammatory and hormonal drivers, the cellular aging dyn…

observational 2023

Real-World Evidence: How Long Do Our Patients Fast?-Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases

Cancers ·doi:10.3390/cancers15041311

BACKGROUND: Despite the key role of optimized fasting in modern perioperative patient management, little current data exist on perioperative fasting intervals in routine clinical practice. METHODS: In this multicenter prospective study, th…